Canada's industry group proposes institute for demonstrating medtech value
This article was originally published in RAJ Devices
Canadian medical technology industry association MEDEC is proposing to develop an institute to demonstrate the economic value of medical technology in Canada1.
You may also be interested in...
A European pilot project that lets drug companies developing innovative products receive scientific advice from two EU member states at the same time is proving its worth during the pandemic.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Celgene's Reblozyl for treating transfusion-dependent anemia in adult patients with myelodysplastic syndromes or beta thalassemia. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).